# Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

> **NCT02118584** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 1822 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrolizumab

## Key facts

- **NCT ID:** NCT02118584
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-15
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 1822 (ACTUAL)
- **Why stopped:** The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118584, "Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02118584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*